^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
05/04/2023
Excerpt:
Pancreatic Adenocarcinoma….PRINCIPLES OF SYSTEMIC THERAPY….Other Recommended Regimens... Nivolumab + ipilimumab (if TMB-H [≥10 mut/Mb]) (category 2B)